Last reviewed · How we verify
Continuation of therapeutic dose anticoagulation
Continuation of therapeutic-dose anticoagulation maintains inhibition of blood coagulation cascade to prevent thrombotic events.
Continuation of therapeutic-dose anticoagulation maintains inhibition of blood coagulation cascade to prevent thrombotic events. Used for Venous thromboembolism prevention or treatment, Atrial fibrillation stroke prevention, Acute coronary syndrome.
At a glance
| Generic name | Continuation of therapeutic dose anticoagulation |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Anticoagulant (class-level; specific agent varies) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is a therapeutic strategy rather than a single drug entity, involving the ongoing administration of anticoagulant agents (such as warfarin, direct oral anticoagulants, or heparins) at doses sufficient to achieve therapeutic anticoagulation. The mechanism depends on the specific anticoagulant used but generally involves inhibition of coagulation factors or platelet function to reduce thrombus formation.
Approved indications
- Venous thromboembolism prevention or treatment
- Atrial fibrillation stroke prevention
- Acute coronary syndrome
- Mechanical heart valve thromboprophylaxis
Common side effects
- Bleeding (major)
- Bleeding (minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation (PHASE4)
- Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care (PHASE3)
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation (EARLY_PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: